OBJECTIVE: To evaluate whether maternal human immunodeficiency virus type 1 (HIV-1) RNA levels in the serum/plasma of mothers at or close to the time of delivery affects the rate of disease progression among vertically HIV-1-infected children and whether it correlates with other parameters affecting infant disease progression. METHODS: International meta-analysis of eight studies with 574 HIV-1 infected infants with available maternal HIV-1 RNA measurements at or close to delivery and clinical follow-up. The primary outcome was disease progression (stage C disease or death, n = 178). Cohort-stratified Cox models were used. RESULTS: Higher maternal HIV-1 RNA level at or close to delivery significantly increased disease progression risk [hazard ratio (HR), 1.25; 95% confidence interval (CI), 1.04-1.52 per 1 log10 increase; P = 0.02) with a borderline effect on mortality (HR, 1.26; 95% CI, 0.96-1.65; P = 0.10]. The association with disease progression risk was strong in the first 6 months of life (HR, 1.77; 95% CI, 1.28-2.45; P = 0.001), but not subsequently (HR, 1.03; 95% CI, 0.81-1.30). Maternal HIV-1 RNA, early infant HIV-1 RNA (at 30-200 days after birth) and infant CD4 were independent predictors of disease progression in the first 6 months. Maternal HIV-1 RNA at or close to delivery correlated with early infant HIV-1 RNA (r = 0.26, P < 0.001). Effects were independent of maternal and infant treatment. CONCLUSIONS: Higher maternal HIV-1 RNA at or close to delivery strongly predicts disease progression for HIV-1-infected infants, especially in their first 6 months of life and correlates with the early peak of viremia in the infected child.
OBJECTIVE: To evaluate whether maternal human immunodeficiency virus type 1 (HIV-1) RNA levels in the serum/plasma of mothers at or close to the time of delivery affects the rate of disease progression among vertically HIV-1-infectedchildren and whether it correlates with other parameters affecting infant disease progression. METHODS: International meta-analysis of eight studies with 574 HIV-1 infectedinfants with available maternal HIV-1 RNA measurements at or close to delivery and clinical follow-up. The primary outcome was disease progression (stage C disease or death, n = 178). Cohort-stratified Cox models were used. RESULTS: Higher maternal HIV-1 RNA level at or close to delivery significantly increased disease progression risk [hazard ratio (HR), 1.25; 95% confidence interval (CI), 1.04-1.52 per 1 log10 increase; P = 0.02) with a borderline effect on mortality (HR, 1.26; 95% CI, 0.96-1.65; P = 0.10]. The association with disease progression risk was strong in the first 6 months of life (HR, 1.77; 95% CI, 1.28-2.45; P = 0.001), but not subsequently (HR, 1.03; 95% CI, 0.81-1.30). Maternal HIV-1 RNA, early infantHIV-1 RNA (at 30-200 days after birth) and infantCD4 were independent predictors of disease progression in the first 6 months. Maternal HIV-1 RNA at or close to delivery correlated with early infantHIV-1 RNA (r = 0.26, P < 0.001). Effects were independent of maternal and infant treatment. CONCLUSIONS: Higher maternal HIV-1 RNA at or close to delivery strongly predicts disease progression for HIV-1-infectedinfants, especially in their first 6 months of life and correlates with the early peak of viremia in the infectedchild.
Authors: Kartik K Venkatesh; Guy de Bruyn; Edmore Marinda; Kennedy Otwombe; Ronelle van Niekerk; Michael Urban; Elizabeth W Triche; Stephen T McGarvey; Mark N Lurie; Glenda E Gray Journal: J Trop Pediatr Date: 2010-07-03 Impact factor: 1.165
Authors: Jennifer A Slyker; Barbara L Lohman-Payne; Sarah L Rowland-Jones; Phelgona Otieno; Elizabeth Maleche-Obimbo; Barbra Richardson; Carey Farquhar; Dorothy Mbori-Ngacha; Vincent C Emery; Grace C John-Stewart Journal: AIDS Date: 2009-01-02 Impact factor: 4.177
Authors: T Déirdre Hollingsworth; Oliver Laeyendecker; George Shirreff; Christl A Donnelly; David Serwadda; Maria J Wawer; Noah Kiwanuka; Fred Nalugoda; Aleisha Collinson-Streng; Victor Ssempijja; William P Hanage; Thomas C Quinn; Ronald H Gray; Christophe Fraser Journal: PLoS Pathog Date: 2010-05-06 Impact factor: 6.823
Authors: Samuel Alizon; Viktor von Wyl; Tanja Stadler; Roger D Kouyos; Sabine Yerly; Bernard Hirschel; Jürg Böni; Cyril Shah; Thomas Klimkait; Hansjakob Furrer; Andri Rauch; Pietro L Vernazza; Enos Bernasconi; Manuel Battegay; Philippe Bürgisser; Amalio Telenti; Huldrych F Günthard; Sebastian Bonhoeffer Journal: PLoS Pathog Date: 2010-09-30 Impact factor: 6.823
Authors: Julia G Prado; Andrew Prendergast; Christina Thobakgale; Claudia Molina; Gareth Tudor-Williams; Thumbi Ndung'u; Bruce D Walker; Philip Goulder Journal: J Virol Date: 2010-01 Impact factor: 5.103